Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

638
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
638
Bone Disorders01:29

Bone Disorders

4.8K
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
4.8K
Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

3.5K
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
3.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K
Bone Remodeling01:40

Bone Remodeling

39.5K
Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
39.5K
Hormones and Bone Tissue01:17

Hormones and Bone Tissue

3.3K
The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
3.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sex- and age-specific comorbidity networks associated with osteoporosis and fragility fractures in nationwide data.

Bone·2026
Same author

[Anabolic treatment in geriatric patients with osteoporosis].

Zeitschrift fur Gerontologie und Geriatrie·2026
Same author

[Diagnosis and management of diabetes and co-existing osteoporosis (Update 2026)].

Wiener klinische Wochenschrift·2026
Same author

Digitally enhanced fracture liaison service in Austria-a feasibility analysis.

Archives of osteoporosis·2026
Same author

Low-Dose Methotrexate and Bone Health: Pathophysiological and Clinical Perspectives.

Journal of clinical medicine·2026
Same author

Effects of high-dose methotrexate on bone metabolism: A narrative literature review.

Bone reports·2026

Related Experiment Video

Updated: Nov 19, 2025

A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders
11:47

A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders

Published on: June 8, 2014

11.9K

New therapeutic options for bone diseases.

Roland Kocijan1,2,3,4, Judith Haschka5,6,7, Julia Feurstein5,6,7

  • 1Ludwig Boltzmann Institute of Osteology, Hanusch Hospital of OEGK and AUVA Trauma Centre Meidling, Heinrich-Collin-Straße 30, 1140, Vienna, Austria. roland.kocijan@osteologie.lbg.ac.at.

Wiener Medizinische Wochenschrift (1946)
|January 29, 2021
PubMed
Summary

New anabolic therapies, including sclerostin antibodies, offer promising treatments for osteoporosis and rare bone diseases like XLH and HPP. Long-term data are crucial to confirm sustained patient benefits.

Keywords:
Asfotase alfaBurosumabRare bone diseasesRomosozumabSclerostin antibody

More Related Videos

Murine Hind Limb Long Bone Dissection and Bone Marrow Isolation
07:17

Murine Hind Limb Long Bone Dissection and Bone Marrow Isolation

Published on: April 14, 2016

86.2K
Semiautomated Longitudinal Microcomputed Tomography-based Quantitative Structural Analysis of a Nude Rat Osteoporosis-related Vertebral Fracture Model
07:12

Semiautomated Longitudinal Microcomputed Tomography-based Quantitative Structural Analysis of a Nude Rat Osteoporosis-related Vertebral Fracture Model

Published on: September 28, 2017

8.4K

Related Experiment Videos

Last Updated: Nov 19, 2025

A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders
11:47

A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders

Published on: June 8, 2014

11.9K
Murine Hind Limb Long Bone Dissection and Bone Marrow Isolation
07:17

Murine Hind Limb Long Bone Dissection and Bone Marrow Isolation

Published on: April 14, 2016

86.2K
Semiautomated Longitudinal Microcomputed Tomography-based Quantitative Structural Analysis of a Nude Rat Osteoporosis-related Vertebral Fracture Model
07:12

Semiautomated Longitudinal Microcomputed Tomography-based Quantitative Structural Analysis of a Nude Rat Osteoporosis-related Vertebral Fracture Model

Published on: September 28, 2017

8.4K

Area of Science:

  • Endocrinology and Bone Metabolism
  • Pharmacology of Bone Diseases

Background:

  • Recent advancements have introduced novel therapeutic agents for managing common and rare bone disorders.
  • The landscape of bone disease treatment is evolving with new drug approvals and ongoing research.

Purpose of the Study:

  • To review the latest treatment options for bone diseases, focusing on sclerostin antibodies and specific therapies for rare conditions.
  • To highlight the anabolic potential of romosozumab for severe osteoporosis and the investigation of other sclerostin antibodies for rare bone diseases.

Main Methods:

  • Literature review of recent clinical studies and drug approvals for bone diseases.
  • Analysis of treatment efficacy and safety data for new therapeutic agents.

Main Results:

  • Romosozumab, a sclerostin antibody, is approved for postmenopausal osteoporosis, demonstrating anabolic effects beneficial for severe cases.
  • Investigational sclerostin antibodies are being explored for rare bone diseases like osteogenesis imperfecta.
  • Specific therapies for X-linked hypophosphatemia (XLH) and hypophosphatasia (HPP) show promising results in pediatric and adult populations with severe disease courses.

Conclusions:

  • Emerging anabolic therapies and targeted treatments offer new hope for patients with various bone diseases.
  • While current data are promising, long-term studies are essential to evaluate the sustained efficacy and safety of these novel treatments.